Risultati e situazione finanziariaSalute - farmaceutica - biotech
First Patient Dosed in Phase 1 Trial Evaluating Transgene’s and BioInvent's BT-001 in Patients with Rectal Cancer
05/11/2026 08:00
AMFPubblicazione immediata
Transgene and University of Copenhagen are collaborating on the investigatorsponsored OV-PRIME-R trial evaluating armed oncolytic virus BT-001 combined with an anti-PD1 in patients with localized rectal cancer with proficient mismatch repair status1
First Patient Dosed in Phase 1 Trial
Evaluating Transgene’s and BioInvent’s BT-001 in Patients with Rectal Cancer
Transgene and University of Copenhagen are collaborating on the investigatorsponsored OV-PRIME-R trial evaluating armed oncolytic virus BT-001 combined with an anti-PD1 in patients with localized rectal cancer with proficient mismatch repair status1
Strasbourg, France, November 5, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer and Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Denmark, today announce that the first patient with proficient mismatch repair (pMMR) rectal cancer has successfully been dosed in the Phase 1 OV-PRIME-R2 trial. The investigator-sponsored trial is evaluating BT-001, an armed oncolytic virus administered via intratumoral injection which will be followed by intravenous pembrolizumab3. This population, which represents approximately 95% of rectal cancer cases, has to date shown poor response to immunotherapy alone.
Henry G. Smith, PhD, Associate Professor and consultant surgeon at Abdominal Center K, Bispebjerg and Frederiksberg Hospital University of Copenhagen and Principal Investigator, commented: “We are excited to launch this investigator-sponsored trial, which explores an innovative approach to treating rectal cancer in patients with proficient mismatch repair status. By combining BT-001, an armed oncolytic virus, with anti-PD-1 therapy, in patients with localized disease, we aim to enhance the immune response and potentially improve outcomes for patients by reducing the risks of relapse or even reducing the number who need surgery at all. This study represents an important step toward more effective and less toxic treatment strategies for this underserved population.”
“We are proud to support this investigator-sponsored trial in collaboration with the University of Copenhagen, evaluating BT-001 in patients with rectal cancer at high risk of relapse and severe toxicities from standard of care,” added Emmanuelle Dochy, MD, Chief Medical Officer of
Transgene. “BT-001 has already demonstrated excellent tolerability and the ability to transform “cold” tumors into biologically active ones. This study aims to further validate its potential to improve outcomes and quality of life for cancer patients.”
1 pMMR proficient mismatch repair
2 Oncolytic Virotherapy to enhance PReoperative IMmunotherapy Efficacy in pMMR Rectal cancer - OV-PRIME-R - EUCT number:
2025-524375-23-00
3 anti PD-1 KEYTRUDA® therapy, registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ,